Drug Profile
Ifinatamab deruxtecan - Daiichi Sankyo Company
Alternative Names: DS-7300; DS-7300a; I-DXd; MK-2400Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Merck & Co
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer; Small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 12 Apr 2024 Daiichi Sankyo in collaboration with Merck Sharp & Dohme plans Ib/II IDeate-Lung03 trial in Small cell lung cancer (Combination therapy, First-line therapy) in June 2024 (IV) (NCT06362252)
- 29 Mar 2024 Daiichi Sankyo plans a phase II trial for Solid tumors (Second-line therapy or greater, Metastatic disease) in March 2024 (NCT06330064)
- 12 Jan 2024 Daiichi Sankyo in collaboration with Merck Sharp & Dohme plans a phase III IDeate-Lung02 (IDeate-2) trial for Small cell lung cancer (Second-line therapy or greater) (IV) in Japan, USA, Europe and Asia in March 2024 (NCT06203210)